Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

Employee Rating

3.6More
TypePublic
HQLexington, US
Founded2000
Size (employees)55 (est)-5%
Websitecuris.com
Curis was founded in 2000 and is headquartered in Lexington, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Curis Office Locations

Curis has an office in Lexington
Lexington, US (HQ)
4 Maguire Rd
Show all (1)
Report incorrect company information

Curis Financials and Metrics

Curis Revenue

Curis's revenue was reported to be $9.90 m in FY, 2017
USD

Revenue (Q3, 2018)

2.8m

Net income (Q3, 2018)

(7.2m)

EBIT (Q3, 2018)

(6.4m)

Market capitalization (14-Dec-2018)

27.8m

Closing stock price (14-Dec-2018)

0.8

Cash (30-Sep-2018)

25.6m

EV

39.4m
Curis's current market capitalization is $27.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

15.0m9.8m7.9m7.5m9.9m

Revenue growth, %

(34%)(20%)(4%)

General and administrative expense

11.3m12.9m15.6m14.1m

R&D expense

1.1m26.7m31.6m45.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

7.2m1.3m4.8m1.8m1.7m2.1m2.0m1.7m1.7m1.8m2.1m2.1m2.4m2.5m2.4m2.8m

General and administrative expense

2.8m2.8m2.9m2.7m3.5m3.4m2.8m3.6m3.4m4.7m3.5m3.8m3.4m4.0m3.6m4.1m

R&D expense

121.9k3.1m3.3m3.7m4.7m5.9m4.0m6.8m8.8m6.8m13.5m11.3m13.4m8.3m6.5m5.0m

Operating expense total

7.1m6.0m6.3m6.5m32.7m9.5m6.9m10.5m12.4m29.5m17.2m15.2m16.9m12.4m10.2m9.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.6m7.7m33.1m26.0m38.3m

Accounts Receivable

1.5m2.0m2.1m2.5m3.1m

Inventories

495.3k489.8k1.2m1.3m

Current Assets

60.2m52.2m85.5m48.2m64.3m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(12.3m)(18.7m)(59.0m)(60.4m)(53.3m)

Depreciation and Amortization

141.5k155.1k160.8k193.0k235.0k

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(8.1m)(5.6m)(7.5m)(13.0m)(31.8m)(40.0m)(45.5m)(9.4m)(20.7m)(49.1m)(15.7m)(29.8m)(45.3m)(10.7m)(19.4m)(26.6m)

Depreciation and Amortization

104.4k37.0k74.8k114.1k82.4k123.1k34.3k90.0k141.0k55.0k113.0k176.0k53.0k99.0k139.0k

Accounts Payable

436.4k395.2k345.5k2.8m(154.0k)75.6k4.9m3.9m5.1m5.9m

Cash From Operating Activities

(4.0m)(10.0m)(12.1m)(14.5m)(19.0m)(8.0m)(18.8m)(26.4m)(15.1m)(24.4m)(40.8m)(10.0m)(16.9m)(25.1m)
USDY, 2018

EV/EBIT

-6.1 x

EV/CFO

-1.6 x

Financial Leverage

56.6 x
Show all financial metrics
Report incorrect company information

Curis Online and Social Media Presence

Embed Graph
Report incorrect company information

Curis News and Updates

Curis to Present at the 60th Annual Meeting of the American Society of Hematology

LEXINGTON, Mass., Nov. 20, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of...

Curis to Release Third Quarter Financial Results and Hold Conference Call on November 1, 2018

LEXINGTON, Mass., Oct. 23, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2018 financial...

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Oct. 5, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2018, the independent Compensation Committee of...

Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass., Sept. 26, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Cantor...

Curis Announces Leadership Change

LEXINGTON, Mass., Sept. 24, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced a change in leadership with the appointment of James E. Dentzer as...
Show more
Report incorrect company information

Curis Company Life and Culture

Report incorrect company information

Curis Frequently Asked Questions

  • When was Curis founded?

    Curis was founded in 2000.

  • How many employees does Curis have?

    Curis has 55 employees.

  • What is Curis revenue?

    Latest Curis annual revenue is $9.9 m.

  • What is Curis revenue per employee?

    Latest Curis revenue per employee is $180 k.

  • Who are Curis competitors?

    Competitors of Curis include Ourotech, Cleveland BioLabs and Heat Biologics.

  • Where is Curis headquarters?

    Curis headquarters is located at 4 Maguire Rd, Lexington.

  • Where are Curis offices?

    Curis has an office in Lexington.

  • How many offices does Curis have?

    Curis has 1 office.